

- 1 introduction, respiratory insufficiency**
- 2 spirometric classification, restrictive**
- 3 and obstructive diseases**
- 4 ventilation/ to perfusion ratio and other amendments**

Outline ...

- **Context** – four possible disturbances of pulmonary function; insufficiently
- **Static characteristics** of the lung – intrapleural pressure, surfactant, **restrictive** disease
- **Dynamic** characteristics of the lung – **obstructive** disease
- **Typical obstructive** diseases
- **Typical restrictive** disease – **lung fibrosis**
- **Assessment** of ventilatory // = **spirometry** etc.

Selected spirometric parameters and tests

-Breathing in rest: ventilatory rate (f/min) (~ 12 breaths / min)

-Minute ventilaton (volume/min) 6-8 L/min

- FVC - Forced vital capacity

Total volume exhaled during the forced expiration

f: $[21.7 - (0.101 \times \text{age}[y])] \times (\text{cm}) = (\text{mL})$

m: $[27.63 - (0.112 \times \text{age}[y])] \times (\text{cm}) = (\text{mL})$

Values between 80 to 120 % of predicted are considered to be normal

-MVV (Vmax) = Maximal voluntary ventilation

maximal tidal volume (TV) and maximal ventilatory rate
measured for 10 – 30 sec

$> 40 \text{ L/min}$


- Ventilatory reserve:

minute ventilation / MVV

$> 1 : 5$

$= 1 : 2$


Normal values for FVC, FEV1 and FEV 25-75%



Regression equation for vital capacity:

Women: $[21.7 - (0.101 \times \text{age}[y])] \times h$
(cm) = (mL)

Men: $[27.63 - (0.112 \times \text{age}[y])] \times h$
(cm) = (mL)



Restrictive diseases

anatomical and/or functional loss of surface for gas exchange

resection

atelectasis

lung edema

lung fibrosis

thoracic deformities / impaired breathing movements

pneumonia


pneumothorax

Characteristics


- decreased vital capacity (VC)
- decreased function residual capacity (FRC)/
=expiratory reserve vol. + residual vol.
- decreased compliance
- normal shape of flow volume loops
- more negative intrapleural pressure during inspiration
- increased in pulmonary vascular resistance
- hypoxemia


Possible respiratory system disturbances


- // **ventilation**
- // **perfusion**
- // **distribution** of ventilation and perfusion
= ventilation perfusion mismatch
- // **diffusion**





Spirogram - **restrictive** disease




















process	compartment	$\dot{V}O_2$ l/min	$\dot{V}O_2$ l	P_{O_2} mm Hg	$\dot{V}CO_2$ l/min	$\dot{V}CO_2$ l	P_{CO_2} mm Hg
	air	0.25	∞	150	0.20	≈ 0	≈ 0
ventilation	airway	0.25	0.03	—	0.20	0.02	—
	alveolus		0.40	100		0.17	40
	lung						
diffusion	arterial	0.25	0.80	90–100	0.20	2.70	40
circulation	capillary						
diffusion	venous			35–45			45
metabolism	extracellular	0.25	0.30	40	0.20	3.30	45
	intracellular						
	tissue						
	mitochondria			<5			>45
		0.25	1.53		0.20	6.19	




* disturbance
 1 mm Hg = 0.133 kPa (see A3)




* disturbance
 1 mm Hg = 0.133 kPa (see A3)




ADP = adenosine diphosphate
ATP = adenosine triphosphate






frontal



sagittal

A INSPIRATION

External intercostal muscles slope obliquely between ribs, *forward* and downward. Because the attachment to the lower rib is farther forward from the axis of rotation, contraction raises the lower rib more than it depresses the upper rib.





B BUCKET-HANDLE AND WATER-PUMP-HANDLE EFFECTS




C EXPIRATION


Internal intercostal muscles slope obliquely between ribs, *backward* and downward, depressing the upper rib more than raising the lower rib.










Pressure – Volume Static Curves





Pressure – Volume Static Curves




Change in lung volume from RV (liters)











760 mmHg = 1 atm = 1000 cmH₂O = 101 kPa = ~100 %


1 dyne = 10 uN, 1 Pa = 1 N/m²




Stability of alveoli




Compliance – effect of surfactant




A EFFECT OF SURFACE TENSION ON COMPLIANCE




B FLAT AIR-WATER INTERFACE



C DEFINITION OF SURFACE TENSION



D SPHERICAL AIR-WATER INTERFACE



alveolar space
alveolar surface




hypophase

granular pneumocyte

alveolar interstitium

endothelial cell

blood capillary




During inflation, the alveolus has expanded from a radius of 100 μm to one of 150 μm , greatly reducing the surface density of the surfactant. Thus, surface tension and elastic recoil rise, putting a "brake" on expansion.

$$P = T / (2R)$$

Rapidly expanding alveolus

Slowly expanding alveolus

Because the radius of this alveolus has expanded from 100 μm to only 120 μm , its surfactant is less diluted, putting less of a "brake" on expansion.



bez surfaktantu:

$\uparrow R$

$$P = T / (2R)$$

se surfaktantem:

$\uparrow T \quad \uparrow R$

$$P = T / (2R)$$

bez surfaktantu:

$\downarrow R$

$$P = T / (2R)$$

se surfaktantem:

$\downarrow T \quad \downarrow R$

$$P = T / (2R)$$

The „most important“ measure of respiratory system function

- pO_2 & pCO_2 in arterial blood - („Astrup“)
- O_2 solubility in water is low => need of Hemoglobin
- **$pO_2 = 13,3 \text{ kPa} = 100 \text{ Torr}$**
- Conversion: $1 \text{ Atm} = 10 \text{ m H}_2\text{O} = 100 \text{ kPa} = 760 \text{ Torr} = 760 \text{ mmHg}$
..... $1 \text{ kPa} = 10 \text{ cm H}_2\text{O} = 7,6 \text{ Torr}$
- **$pCO_2 = 40 \text{ Torr} = 5,3 \text{ kPa}$**

Alveolar ventilation

$$V_{CO_2} = F_A CO_2 \times V_A$$

$$V_A = V_{CO_2} / F_A CO_2$$


$$P_A CO_2 = F_A CO_2 \times \text{Barometric pressure}$$


$$V_A = k_1 \times V_{CO_2} / P_A CO_2$$

$$P_A CO_2 = k_2 \times \underset{\text{STPD}}{V_{CO_2}} / \underset{\text{BTPS}}{V_A}$$

$\frac{P \times V}{T} = R$	$\frac{(P - P_{H_2O}) \times V_{BTPS}}{273 + t^{\circ} \text{patient}} = \frac{760 \times V_{BTPS}}{273}$
----------------------------	---


$$P_A CO_2 [\text{torr}] = 0,863 \times V_{CO_2} [\text{ml/min STPD}] / V_A [\text{l/min BTPS}]$$





$$P_ACO_2[\text{torr}] = 0,863 \times VCO_2[\text{ml/min STPD}] / VA[\text{l/min BTPS}]$$

Alveolar Ventilation Controls Rate of Breathing by Influencing pCO₂ and pO₂



Ventilation disorders

- **Lung impairment (mechanical properties change)**
 - **Obstructive disease** - $\uparrow$ increased resistance R of airways (R = “dynamic lung resistance”)
 - **Restrictive disease** – $\downarrow$ decreased lung compliance C ($\uparrow$ static resistance” `; $C = 1 / \text{static lung resistance}$)
- **Chest wall impairment**
 - $\downarrow$ decreased C of chest wall – severe scoliosis, extensive fibrosis, serial fractures
- **Insufficient activity of respiratory muscles** ($//$ innervation or $//$ muscle strength , $//$ of CNS) – E.g..
Respiratory centre suppression in barbiturate poisoning, myasthenia gravis

Lung fibrosis = Interstitial lung disease (ILD)


- = diffuse parenchymal lung disease
- Inflammation in alveolar wall leads to scarring and collagen deposition
- Chest X-ray, pulmonary function testing, (lung biopsy)
- Affect the alveolar wall or the interstice of the lung (alveolar epithelium, capillary endothelium, basal membrane, interstice and perilymphatic tissue)
- Fibrosis may be a late sign

Causes of lung fibrosis/ ILD

- Inhalation of particles
 - 1. Asbestosis, silicosis, pneumoconiosis, = **Pneumokonioser**
 - 2. hypersensitivity (farmer's lung) = **Alveolitis allergica**
- Drug induced (Abio, chemo, Antiarrhythmic) =
- Connective tissue disease: Systemic sclerosis, Dermatomyositis, SLE, RA
- **Infection:** Atypical pneumonia, pneumocystis, TBC
- Lymphangitic carcinoma = **maligne sygdrome**
Idiopathic: **Sarcoidosis**
- Idiopathic pulmonary fibrosis = **Alveolitis fibrosa**


Fibrosing alveolitis= Idiopathic pulmonary fibrosis

- Unknown cause – Autoimmunity?
- People after 50 / 3 years life expectancy
- Symptoms:
 - Tachypnoe, cyanosis, finger clubbing
- Dg:
 - Chest X-ray
 - HRCT
 - Spirometry/whole body pletysmography
 - Blood gas analysis
 - Inflammatory and autoimmunity testing
- Biopsy and histology: Histology: Usual interstitial pneumonia




Possible respiratory system disturbances

- // **ventilation**
- // **perfusion**
- // **distribution** of ventilation and perfusion
= ventilation perfusion mismatch
- // **diffusion**



Ventilation



Is carried out by respiratory muscles, that change volume of thorax.


Volume changes cause changes of pressures

Changes of pressure in alveoli cause air flow (
↑ pressure – expiration;
↓ pressure – inspiration)
flow behaves according to Ohm's law


Ventilation disorders

- **Lung impairment (mechanical properties change)**
 - **Obstructive disease** - $\uparrow$ increased resistance R of airways (R = “dynamic lung resistance”)
 - **Restrictive disease** – $\downarrow$ decreased lung compliance C ($\uparrow$ static resistance” `; $C = 1 / \text{static lung resistance}$)
- **Chest wall impairment**
 - $\downarrow$ decreased C of chest wall – severe scoliosis, extensive fibrosis, serial fractures
- **Insufficient activity of respiratory muscles** ($//$ innervation or $//$ muscle strength , $//$ of CNS) – E.g..
Respiratory centre suppression in barbiturate poisoning, myasthenia gravis


Normal/ Restrictive/ Obstructive



Why the airplane flies?



Bronchiolus narrows (broncho-constriction, mucus...)



What did we cover

- **Context** – four possible disturbances of pulmonary function; insufficiently
- **Static characteristics** of the lung – intrapleural pressure, surfactant, **restrictive** disease
- **Dynamic** characteristics of the lung – **obstructive** disease
- **Typical obstructive** diseases
- **Typical restrictive** disease – **lung fibrosis**
- **Assessment** of ventilatory // = **spirometry** etc.

END OF THE LECTURE

Thanks for your attention

Warning: neither the PDF, nor the PPT, PPTX, etc.
versions of this presentation are official study materials.
For internal use only. Do not distribute.

Contact: Petr.Marsalek@LF1.CUNI.CZ

First Medical Faculty, Institute of Pathological Physiology

